KALVISTA PHARMACEUTICALS INC's ticker is KALV and the CUSIP is 483497103. A total of 92 filers reported holding KALVISTA PHARMACEUTICALS INC in Q4 2022. The put-call ratio across all filers is 0.09 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2022 | $11,267,000 | +143.6% | 776,510 | +65.2% | 0.00% | +100.0% |
| Q2 2022 | $4,626,000 | -76.7% | 470,133 | -65.1% | 0.00% | -66.7% |
| Q1 2022 | $19,851,000 | -17.2% | 1,346,742 | -25.7% | 0.00% | -25.0% |
| Q4 2021 | $23,966,000 | -25.0% | 1,811,505 | -1.1% | 0.00% | -20.0% |
| Q3 2021 | $31,958,000 | -25.7% | 1,831,441 | +2.1% | 0.01% | -28.6% |
| Q2 2021 | $42,997,000 | +10.9% | 1,794,518 | +18.9% | 0.01% | 0.0% |
| Q1 2021 | $38,767,000 | +133.9% | 1,509,025 | +72.9% | 0.01% | +133.3% |
| Q4 2020 | $16,572,000 | +72.3% | 872,656 | +14.2% | 0.00% | +50.0% |
| Q3 2020 | $9,618,000 | +291.6% | 763,959 | +276.4% | 0.00% | +100.0% |
| Q2 2020 | $2,456,000 | +61.0% | 202,959 | +1.8% | 0.00% | – |
| Q1 2020 | $1,525,000 | -60.6% | 199,315 | -8.2% | 0.00% | -100.0% |
| Q4 2019 | $3,867,000 | +1176.2% | 217,088 | +732.7% | 0.00% | – |
| Q3 2019 | $303,000 | – | 26,069 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Saturn V Capital Management LP | 1,810,246 | $17,432,669 | 7.30% |
| TCG Crossover Management, LLC | 3,395,495 | $32,698,617 | 4.82% |
| TANG CAPITAL MANAGEMENT LLC | 3,440,345 | $33,130,522 | 4.68% |
| VR Adviser, LLC | 2,916,667 | $28,087,503 | 2.96% |
| Frazier Life Sciences Management, L.P. | 3,238,859 | $31,190,212 | 2.07% |
| Nan Fung Group Holdings Ltd | 234,573 | $2,258,938 | 1.83% |
| DAFNA Capital Management LLC | 605,532 | $5,831,273 | 1.81% |
| Opaleye Management Inc. | 500,000 | $4,815,000 | 1.57% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 530,400 | $5,107,752 | 1.55% |
| MPM BioImpact LLC | 577,958 | $5,565,736 | 1.49% |